MYC and lymphoma: Because c-Myc and mTOR signaling converges at 4E-BP-1 in a c-Myc driven lymphoma mouse model [47], we hypothesized that a combination therapy with JQ1 and MLN0128 might augment anti-tumor effect in our disease model.